X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ACTAVIS
Dec-14
ALKEM LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,58918,853-   
Low Rs1,23211,500-   
Sales per share (Unadj.) Rs417.53,394.9-  
Earnings per share (Unadj.) Rs56.3-423.7-  
Cash flow per share (Unadj.) Rs64.7311.5-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.97,363.5-  
Shares outstanding (eoy) m119.57265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.5 75.6%   
Avg P/E ratio x25.1-35.8 -69.9%  
P/CF ratio (eoy) x21.848.7 44.7%  
Price / Book Value ratio x4.82.1 233.6%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6534,035,446 4.2%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM41,792.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-5,215.2-  
INCOME DATA
Net Sales Rs m49,915902,715 5.5%  
Other income Rs m1,645-2,253 -73.0%   
Total revenues Rs m51,561900,462 5.7%   
Gross profit Rs m8,482115,967 7.3%  
Depreciation Rs m1,006195,471 0.5%   
Interest Rs m67128,473 2.4%   
Profit before tax Rs m8,451-110,230 -7.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,086 0.0%   
Tax Rs m1,606-5,667 -28.3%   
Profit after tax Rs m6,731-112,649 -6.0%  
Gross profit margin %17.012.8 132.3%  
Effective tax rate %19.05.1 369.6%   
Net profit margin %13.5-12.5 -108.1%  
BALANCE SHEET DATA
Current assets Rs m27,062475,615 5.7%   
Current liabilities Rs m15,324346,863 4.4%   
Net working cap to sales %23.514.3 164.9%  
Current ratio x1.81.4 128.8%  
Inventory Days Days6758 114.6%  
Debtors Days Days4166 62.3%  
Net fixed assets Rs m12,610110,230 11.4%   
Share capital Rs m2390-   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,0271,957,955 1.8%   
Long term debt Rs m1,2121,026,007 0.1%   
Total assets Rs m54,3873,588,288 1.5%  
Interest coverage x13.6-2.9 -473.7%   
Debt to equity ratio x00.5 6.6%  
Sales to assets ratio x0.90.3 364.8%   
Return on assets %13.6-2.3 -580.2%  
Return on equity %19.2-5.8 -334.0%  
Return on capital %24.9-3.0 -825.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,259155,014 4.7%  
From Investments Rs m1,864-371,162 -0.5%  
From Financial Activity Rs m-9,273208,539 -4.4%  
Net Cashflow Rs m-150-7,609 2.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.11 Rs / USD

Compare ALKEM LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: GLENMARK PHARMA  CIPLA  AJANTA PHARMA  MERCK  ABBOTT INDIA  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)

Mar 15, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS